Your browser doesn't support javascript.
loading
The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy.
Moors, Tim E; Maat, Christina A; Niedieker, Daniel; Mona, Daniel; Petersen, Dennis; Timmermans-Huisman, Evelien; Kole, Jeroen; El-Mashtoly, Samir F; Spycher, Liz; Zago, Wagner; Barbour, Robin; Mundigl, Olaf; Kaluza, Klaus; Huber, Sylwia; Hug, Melanie N; Kremer, Thomas; Ritter, Mirko; Dziadek, Sebastian; Geurts, Jeroen J G; Gerwert, Klaus; Britschgi, Markus; van de Berg, Wilma D J.
Afiliación
  • Moors TE; Department of Anatomy and Neurosciences, Clinical Neuroanatomy and Biobanking, Amsterdam Neuroscience, Amsterdam UMC, Location VU University Medical Center, O2 building, room 13 E11, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
  • Maat CA; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • Niedieker D; Department of Anatomy and Neurosciences, Clinical Neuroanatomy and Biobanking, Amsterdam Neuroscience, Amsterdam UMC, Location VU University Medical Center, O2 building, room 13 E11, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
  • Mona D; Department of Biophysics, Ruhr-University Bochum, Universitätsstrasse 150, 44801, Bochum, Germany.
  • Petersen D; Roche Pharma Research and Early Development; Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.
  • Timmermans-Huisman E; Department of Biophysics, Ruhr-University Bochum, Universitätsstrasse 150, 44801, Bochum, Germany.
  • Kole J; Department of Anatomy and Neurosciences, Clinical Neuroanatomy and Biobanking, Amsterdam Neuroscience, Amsterdam UMC, Location VU University Medical Center, O2 building, room 13 E11, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
  • El-Mashtoly SF; Department of Physiology, Amsterdam UMC, Location VU University Medical Center, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
  • Spycher L; Department of Biophysics, Ruhr-University Bochum, Universitätsstrasse 150, 44801, Bochum, Germany.
  • Zago W; Roche Pharma Research and Early Development; Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.
  • Barbour R; Prothena Biosciences Inc, South San Francisco, CA, 94080, USA.
  • Mundigl O; Prothena Biosciences Inc, South San Francisco, CA, 94080, USA.
  • Kaluza K; Roche Pharma Research and Early Development, Therapeutic Modalities; Large Molecule Research, Roche Innovation Center Munich, Nonnenwald 2, 82377, Penzberg, Germany.
  • Huber S; Roche Pharma Research and Early Development, Therapeutic Modalities; Large Molecule Research, Roche Innovation Center Munich, Nonnenwald 2, 82377, Penzberg, Germany.
  • Hug MN; Roche Pharma Research and Early Development; Therapeutic Modalities; Small Molecule Research, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.
  • Kremer T; Roche Pharma Research and Early Development; Therapeutic Modalities; Small Molecule Research, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.
  • Ritter M; Roche Pharma Research and Early Development; Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.
  • Dziadek S; Roche Diagnostics GmbH, Nonnenwald 2, 82377, Penzberg, Germany.
  • Geurts JJG; Roche Pharma Research and Early Development; Oncology Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, Basel, Switzerland.
  • Gerwert K; Department of Anatomy and Neurosciences, Clinical Neuroanatomy and Biobanking, Amsterdam Neuroscience, Amsterdam UMC, Location VU University Medical Center, O2 building, room 13 E11, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
  • Britschgi M; Department of Biophysics, Ruhr-University Bochum, Universitätsstrasse 150, 44801, Bochum, Germany.
  • van de Berg WDJ; Roche Pharma Research and Early Development; Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland. markus.britschgi@roche.com.
Acta Neuropathol ; 142(3): 423-448, 2021 09.
Article en En | MEDLINE | ID: mdl-34115198
ABSTRACT
Various post-translationally modified (PTM) proteoforms of alpha-synuclein (aSyn)-including C-terminally truncated (CTT) and Serine 129 phosphorylated (Ser129-p) aSyn-accumulate in Lewy bodies (LBs) in different regions of the Parkinson's disease (PD) brain. Insight into the distribution of these proteoforms within LBs and subcellular compartments may aid in understanding the orchestration of Lewy pathology in PD. We applied epitope-specific antibodies against CTT and Ser129-p aSyn proteoforms and different aSyn domains in immunohistochemical multiple labelings on post-mortem brain tissue from PD patients and non-neurological, aged controls, which were scanned using high-resolution 3D multicolor confocal and stimulated emission depletion (STED) microscopy. Our multiple labeling setup highlighted a consistent onion skin-type 3D architecture in mature nigral LBs in which an intricate and structured-appearing framework of Ser129-p aSyn and cytoskeletal elements encapsulates a core enriched in CTT aSyn species. By label-free CARS microscopy we found that enrichments of proteins and lipids were mainly localized to the central portion of nigral aSyn-immunopositive (aSyn+) inclusions. Outside LBs, we observed that 122CTT aSyn+ punctae localized at mitochondrial membranes in the cytoplasm of neurons in PD and control brains, suggesting a physiological role for 122CTT aSyn outside of LBs. In contrast, very limited to no Ser129-p aSyn immunoreactivity was observed in brains of non-neurological controls, while the alignment of Ser129-p aSyn in a neuronal cytoplasmic network was characteristic for brains with (incidental) LB disease. Interestingly, Ser129-p aSyn+ network profiles were not only observed in neurons containing LBs but also in neurons without LBs particularly in donors at early disease stage, pointing towards a possible subcellular pathological phenotype preceding LB formation. Together, our high-resolution and 3D multicolor microscopy observations in the post-mortem human brain provide insights into potential mechanisms underlying a regulated LB morphogenesis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Fracciones Subcelulares / Química Encefálica / Alfa-Sinucleína Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Acta Neuropathol Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Fracciones Subcelulares / Química Encefálica / Alfa-Sinucleína Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Acta Neuropathol Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos